R Liu1, J Zhou2, S Xia2, T Li2. 1. Department of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, 300211, China. 16622080858@163.com. 2. Department of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, 300211, China.
Abstract
BACKGROUND: The specific association between PTEN deletion or ERG rearrangement and the recurrence of prostate cancer (PC) treated with radical prostatectomy (RP) or brachytherapy is still unelaborated. Therefore, we performed a comprehensive meta‑analysis to understand the impact of these factors on cancer recurrence. METHODS: A comprehensive literature search was performed in November 2018 based on PUBMED, EMBASE and Web of science database. Hazard ratio (HR) for biochemical recurrence free (BRF) which was defined as a PSA greater than or equal to 0.4 ng/mL after RP or another therapy for any detectable PSA and recurrence-free survival (RFS) which defined the time from the beginning of treatment to the earliest occurrence of local recurrence, distant metastasis or death. Which were extracted from eligible studies. I2 value was used to assess the pooled heterogeneity. RESULT: A total of 6744 patients from 17 studies were included in this analysis Overall, The pooled results showed that PTEN loss predict pooled BRF (HR 1.79, 95% CI 1.49-2.16, P < 0.001) and RFS (HR 1.71, 95% CI 1.50-1.95, P < 0.001) in patients after radical prostatectomy or brachytherapy for prostate cancer. Subgroup analysis revealed that PTEN deletion significantly predicted poor BRF or RFS in heterozygous studies group (HR 1.70, 95% CI 1.31-2.21, P < 0.001). The PTEN deletion also significantly predicted poor BRF or PFS in homozygous studies (HR 2.54, 95% CI 1.89-3.17, P < 0.001). And we had found that there was no significant association between ERG rearrangement and cancer recurrence regardless of PTEN loss or not. In addition, we concluded that Gleason score > 6 significantly predicted the poor BRF or RFS in studies, especially in Gleason score = 4 + 3 (HR 3.16, 95% CI 2.08-4.80, P < 0.01). CONCLUSION: This study presented that PTEN deletion significantly reduce time of BRF or RFS, especially based on homozygous deletion. And we also found ERG rearrangement in tumor cell could not significantly predict BRF or RFS.
BACKGROUND: The specific association between PTEN deletion or ERG rearrangement and the recurrence of prostate cancer (PC) treated with radical prostatectomy (RP) or brachytherapy is still unelaborated. Therefore, we performed a comprehensive meta‑analysis to understand the impact of these factors on cancer recurrence. METHODS: A comprehensive literature search was performed in November 2018 based on PUBMED, EMBASE and Web of science database. Hazard ratio (HR) for biochemical recurrence free (BRF) which was defined as a PSA greater than or equal to 0.4 ng/mL after RP or another therapy for any detectable PSA and recurrence-free survival (RFS) which defined the time from the beginning of treatment to the earliest occurrence of local recurrence, distant metastasis or death. Which were extracted from eligible studies. I2 value was used to assess the pooled heterogeneity. RESULT: A total of 6744 patients from 17 studies were included in this analysis Overall, The pooled results showed that PTEN loss predict pooled BRF (HR 1.79, 95% CI 1.49-2.16, P < 0.001) and RFS (HR 1.71, 95% CI 1.50-1.95, P < 0.001) in patients after radical prostatectomy or brachytherapy for prostate cancer. Subgroup analysis revealed that PTEN deletion significantly predicted poor BRF or RFS in heterozygous studies group (HR 1.70, 95% CI 1.31-2.21, P < 0.001). The PTEN deletion also significantly predicted poor BRF or PFS in homozygous studies (HR 2.54, 95% CI 1.89-3.17, P < 0.001). And we had found that there was no significant association between ERG rearrangement and cancer recurrence regardless of PTEN loss or not. In addition, we concluded that Gleason score > 6 significantly predicted the poor BRF or RFS in studies, especially in Gleason score = 4 + 3 (HR 3.16, 95% CI 2.08-4.80, P < 0.01). CONCLUSION: This study presented that PTEN deletion significantly reduce time of BRF or RFS, especially based on homozygous deletion. And we also found ERG rearrangement in tumor cell could not significantly predict BRF or RFS.
Authors: Gaetano Zafarana; Adrian S Ishkanian; Chad A Malloff; Jennifer A Locke; Jenna Sykes; John Thoms; Wan L Lam; Jeremy A Squire; Maisa Yoshimoto; Varune Rohan Ramnarine; Alice Meng; Omar Ahmed; Igor Jurisica; Igor Jurisca; Michael Milosevic; Melania Pintilie; Theo van der Kwast; Robert G Bristow Journal: Cancer Date: 2012-01-26 Impact factor: 6.860
Authors: Cristina Magi-Galluzzi; Sudhir Isharwal; Sara M Falzarano; Athanasios Tsiatis; Anne Dee; Tara Maddala; Dejan Knezevic; Phillip G Febbo; Jeffrey Lawrence; Eric A Klein Journal: Urology Date: 2018-08-22 Impact factor: 2.649
Authors: Antje Krohn; Tobias Diedler; Lia Burkhardt; Pascale-Sophie Mayer; Colin De Silva; Marie Meyer-Kornblum; Darja Kötschau; Pierre Tennstedt; Joseph Huang; Clarissa Gerhäuser; Malte Mader; Stefan Kurtz; Hüseyin Sirma; Fred Saad; Thomas Steuber; Markus Graefen; Christoph Plass; Guido Sauter; Ronald Simon; Sarah Minner; Thorsten Schlomm Journal: Am J Pathol Date: 2012-06-13 Impact factor: 4.307
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Jacqueline Fontugne; Daniel Lee; Chiara Cantaloni; Christopher E Barbieri; Orazio Caffo; Esther Hanspeter; Guido Mazzoleni; Paolo Dalla Palma; Mark A Rubin; Giovanni Fellin; Juan Miguel Mosquera; Mattia Barbareschi; Francesca Demichelis Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-02-10 Impact factor: 4.254
Authors: Dean A Troyer; Tamara Jamaspishvili; Wei Wei; Ziding Feng; Jennifer Good; Sarah Hawley; Ladan Fazli; Jesse K McKenney; Jeff Simko; Antonio Hurtado-Coll; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; James D Brooks; Jeremy A Squire Journal: Prostate Date: 2015-05-04 Impact factor: 4.104
Authors: J Ishioka; K Saito; M Sakura; M Yokoyama; Y Matsuoka; N Numao; F Koga; H Masuda; Y Fujii; S Kawakami; K Kihara Journal: Br J Cancer Date: 2012-08-23 Impact factor: 7.640
Authors: Milan S Geybels; Min Fang; Jonathan L Wright; Xiaoyu Qu; Marina Bibikova; Brandy Klotzle; Jian-Bing Fan; Ziding Feng; Elaine A Ostrander; Peter S Nelson; Janet L Stanford Journal: Oncotarget Date: 2017-09-15